SUBSCRIBE
SUBSCRIBE
News   Policy

Pharmaceutical Research and Manufacturers of America (PhRMA) Speaks Out Against FDA Biosimilar Flexibility

May 2, 2012 | 
1 min read
PhRMA has spoken out against FDA plans to allow biosimilar manufacturers flexibility in delivery device and formulation choice.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Background with halftone hand hold magnifier and torn papers. Collage element for search concept. Find information in internet browser.
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
The white plane flies against the blue sky, leaving a white trail. Vector illustration
Rare diseases
Prasad’s Departure Could Be ‘Big Win’ for Biotech—Especially Rare Disease Space: Analysts
March 9, 2026
 · 
3 min read
 · 
Tristan Manalac
halftone magazine style banner, dislike, negative rating, hand thumbs down
Complete response letters
Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
FDA
FDA’s Prasad To Depart FDA Following Tumultuous Term as CBER Chief
March 6, 2026
 · 
3 min read
 · 
Heather McKenzie